Welcome to our dedicated page for Corbus Pharmaceu news (Ticker: CRBP), a resource for investors and traders seeking the latest updates and insights on Corbus Pharmaceu stock.
Corbus Pharmaceuticals Holdings, Inc. reports clinical-stage drug-development news in oncology and obesity. Updates center on CRB-701, a next-generation Nectin-4 antibody-drug conjugate licensed from CSPC Megalith Biopharmaceutical, including data presentations in head and neck squamous cell carcinoma and cervical cancer, FDA interactions and Fast Track designations.
Company news also covers CRB-913, a peripherally restricted oral CB1 inverse agonist for obesity, and CRB-601, an anti-integrin monoclonal antibody targeting TGFβ activation. Recurring items include clinical trial disclosures, medical-meeting presentations, management conference appearances, governance changes and operating or financial results.
Corbus Pharmaceuticals (NASDAQ: CRBP) reported that its Compensation Committee approved inducement equity awards for new Chief Medical Officer Leonardo Nicacio, effective August 16, 2026, under Nasdaq Listing Rule 5635(c)(4). The awards were granted outside Corbus’ stockholder-approved equity plans as a material inducement to his employment.
The package includes a nonstatutory stock option for up to 191,676 shares of common stock at an exercise price of $10.09, with a ten-year term, vesting 25% on the first anniversary and the remaining 75% in equal monthly installments over 36 months, subject to continued service. It also includes 58,333 restricted stock units vesting in four equal annual installments, each RSU converting into one share upon vesting, contingent on continued service.
Corbus Pharmaceuticals (NASDAQ: CRBP) reported Q2 2026 net loss of approximately $35.0 million, or $1.81 per share, versus $17.7 million, or $1.44 per share, a year earlier. Operating expenses rose to about $36.2 million from $19.2 million, mainly due to higher clinical costs including a $10.0 million milestone payment under the CRB-701 license.
Corbus obtained FDA clearance for TEMPO-1, a Phase 3 registrational study (n=250) of CRB-701 in second-line oropharyngeal squamous cell carcinoma, with enrollment expected to start in September 2026. The company completed last patient last visit in the 240-patient CANYON-1 Phase 1b obesity study of CRB-913 and plans topline data in September 2026. Leadership was strengthened with a new Chief Medical Officer, Chief Business Officer, and Board member. Corbus held $117.9 million in cash, cash equivalents, and investments as of June 30, 2026, which it expects to fund operations into 2028.
Corbus Pharmaceuticals (NASDAQ: CRBP) reported that the last patient has completed the final clinical visit in its CANYON-1 Phase 1b trial of CRB-913 for obesity, keeping topline data on track for September 2026.
CANYON-1 is a 16‑week, double-blind, placebo-controlled, dose-ranging study in 240 obese, non-diabetic adults in the U.S., testing once-daily oral doses of 20 mg, 40 mg and 60 mg versus placebo with a dose-titration regimen and a 4‑week safety follow-up. CRB-913 is described as a highly peripherally restricted CB1 inverse agonist, aiming to offer an orthogonal, non-incretin oral approach to weight loss. The study follows Phase 1a data indicating differentiated GI tolerability versus GLP‑1 therapies and preclinical mouse data showing approximately 15-fold lower brain penetration than the CB1 inverse agonist monlunabant.
Corbus Pharmaceuticals (NASDAQ: CRBP) reported that the U.S. FDA has cleared initiation of TEMPO-1, a registrational Phase 2 study of CRB-701, a next-generation Nectin-4–targeted antibody drug conjugate, in second-line oropharyngeal squamous cell carcinoma (OPSCC). The randomized controlled trial will enroll approximately 250 patients and compare CRB-701 to investigator’s choice of capecitabine, cetuximab or docetaxel. The primary endpoint is objective response rate to support a potential accelerated approval, with overall survival intended to support potential full approval. Corbus expects to begin enrollment in September 2026.
The FDA decision follows Phase 1/2 data in 2L+ OPSCC at a 3.6 mg/kg dose, where CRB-701 achieved a confirmed objective response rate of 42.9%, median duration of response of 6.3 months, and median progression-free survival of 5.6 months (ongoing). OPSCC is estimated to represent about half of U.S. second-line head and neck cancer cases, with roughly 14,000 patients annually eligible for 2L treatment and about 7,000 deaths. CRB-701 has two FDA Fast Track designations in head and neck squamous cell carcinoma and cervical cancer.
Corbus Pharmaceuticals (NASDAQ: CRBP) appointed Leonardo Viana Nicacio, M.D. as Chief Medical Officer. He brings over 20 years of oncology experience, including leadership roles at Seagen, Stemline, AstraZeneca and Protara.
Corbus plans to initiate the TEMPO-1 registrational CRB-701 study in 2L OPSCC in summer 2026 and expects CANYON-1 CRB-913 obesity data in late summer 2026.
Corbus Pharmaceuticals (NASDAQ:CRBP) reported updated Phase 1/2 data for CRB-701, a Nectin-4 targeted ADC, in second-line (2L) HPV-associated tumors.
At 3.6 mg/kg, confirmed ORR was 42.9% in 2L OPSCC and 34.4% in 2L cervical cancer, with ongoing median DOR of 6.3 and 8.0 months, and PFS of 5.6 and 4.3 months, respectively. In a 317-patient safety population, discontinuations related to CRB-701 were 2.8%. Ocular AEs occurred in 66.2% of patients, with 12.6% Grade 3 and one Grade 4 case; ocular AE-related discontinuations were 1.9%. Corbus plans a registrational 2L OPSCC trial (TEMPO-1) in summer 2026 and has FDA alignment on randomized study designs in 2L OPSCC and 2L cervical cancer.
Corbus Pharmaceuticals (Nasdaq: CRBP) appointed former Evercore Managing Director Nishant Saxena as its first Chief Business Officer and scheduled a May 26, 2026 conference call to review updated Phase 1/2 data for Nectin‑4 ADC CRB-701 in HNSCC and cervical cancer.
The company highlighted expected summer 2026 milestones, including initiating a registrational CRB-701 study in second-line HNSCC and completing the 240-patient CANYON-1 Phase 1b study of obesity candidate CRB-913, plus multiple CRB-701 presentations and an HNSCC KOL event at the 2026 ASCO meeting.
Corbus Pharmaceuticals (NASDAQ: CRBP) appointed pharma executive Brent Pfeiffenberger, PharmD, MBA, President and CEO of Century Therapeutics, to its Board of Directors.
He brings extensive oncology commercialization experience as Corbus advances CRB-701 and CRB-913, with key data readouts and a planned CRB-701 registrational study expected this summer.
Corbus Pharmaceuticals (Nasdaq: CRBP), a clinical-stage company in oncology and obesity, announced that CEO Yuval Cohen will present a corporate overview and hold investor meetings at the RBC Capital Markets Global Healthcare Conference on May 19, 2026, and the Jefferies Global Healthcare Conference on June 4, 2026, both in New York.
Presentations will be webcast. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate targeting Nectin-4-expressing tumors, and CRB-913, an oral, highly peripherally restricted CB1 inverse agonist for obesity.
Corbus Pharmaceuticals (NASDAQ:CRBP) reported Q1 2026 results and pipeline updates in oncology and obesity.
The company recorded a $23.0M net loss and $24.3M operating expenses, with $138.2M in cash expected to fund operations into 2028, while advancing CRB-701 toward registrational studies and completing enrollment in the 240-patient CANYON-1 obesity trial for CRB-913.